Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMDZ
2451
DELISTED
Immune Design Corp.
IMDZ
| $1.36M | ﹤0.01% |
139,800
+28,060
| +25% | +$197K |
|
2452
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.6B
| $1.36M | ﹤0.01% |
30,400
+2,600
| +9% | +$116K |
|
|
ATTU
2453
DELISTED
Attunity Ltd
ATTU
| $1.36M | ﹤0.01% |
189,400
+19,700
| +12% | +$146K |
|
2454
Radiant Logistics
RLGT
$410M
| $1.36M | ﹤0.01% |
253,000
+59,400
| +31% | +$342K |
|
2455
Minerals Technologies
MTX
$2.26B
| $1.35M | ﹤0.01% |
18,509
+6,609
| +56% | +$493K |
|
|
NVLN
2456
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $1.35M | ﹤0.01% |
146,839
-43,271
| -23% | -$417K |
|
|
CORI
2457
DELISTED
Corium International, Inc.
CORI
| $1.35M | ﹤0.01% |
+181,400
| New | +$1.08M |
|
|
ESXB
2458
DELISTED
Community Bankers Trust Corporation
ESXB
| $1.35M | ﹤0.01% |
163,525
+124,551
| +320% | +$999K |
|
2459
Aspen Aerogels
ASPN
$496M
| $1.35M | ﹤0.01% |
302,700
+40,200
| +15% | +$170K |
|
|
CVG
2460
DELISTED
Convergys
CVG
| $1.34M | ﹤0.01% |
+56,530
| New | +$1.32M |
|
2461
Harmony Gold Mining
HMY
$12.2B
| $1.34M | ﹤0.01% |
811,299
-1,477,500
| -65% | -$3.17M |
|
|
ELON
2462
DELISTED
Echelon Corp
ELON
| $1.32M | ﹤0.01% |
256,604
+55,104
| +27% | +$340K |
|
2463
Axcelis
ACLS
$4.38B
| $1.32M | ﹤0.01% |
+63,099
| New | +$1.33M |
|
|
DFT
2464
DELISTED
DuPont Fabros Technology Inc.
DFT
| $1.32M | ﹤0.01% |
21,600
+15,000
| +227% | +$824K |
|
2465
Vaalco Energy
EGY
$606M
| $1.32M | ﹤0.01% |
1,411,700
+91,000
| +7% | +$89.3K |
|
|
BAS
2466
DELISTED
Basis Energy Services, Inc.
BAS
| $1.32M | ﹤0.01% |
+53,000
| New | +$1.47M |
|
2467
Full House Resorts
FLL
$85.4M
| $1.32M | ﹤0.01% |
533,913
+40,000
| +8% | +$94.5K |
|
2468
Star Group
SGU
$418M
| $1.32M | ﹤0.01% |
121,523
-8,629
| -7% | -$85.3K |
|
2469
PennyMac Financial
PFSI
$4.11B
| $1.31M | ﹤0.01% |
78,700
-151,707
| -66% | -$2.51M |
|
2470
Upbound Group
UPBD
$1.15B
| $1.31M | ﹤0.01% |
+112,110
| New | +$1.27M |
|
2471
CVD Equipment Corp
CVV
$53M
| $1.31M | ﹤0.01% |
118,500
+31,400
| +36% | +$346K |
|
|
EVA
2472
DELISTED
Enviva Inc.
EVA
| $1.31M | ﹤0.01% |
47,500
-16,800
| -26% | -$472K |
|
2473
Smart Sand
SND
$217M
| $1.3M | ﹤0.01% |
146,100
+65,000
| +80% | +$737K |
|
|
FRGI
2474
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $1.3M | ﹤0.01% |
+62,866
| New | +$1.43M |
|
2475
Inuvo
INUV
$13.6M
| $1.29M | ﹤0.01% |
126,862
+5,070
| +4% | +$58.1K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.